[TAVI and coronary revascularization].
Combaret N, Bouchant M, Motreff P, Souteyrand G.
Ann Cardiol Angeiol (Paris). 2019 Dec;68(6):423-428. doi: 10.1016/j.ancard.2019.09.019. Epub 2019 Oct 21.
Bleeding complications with PCI.
Satler LF.
Catheter Cardiovasc Interv. 2005 Mar;64(3):373-4. doi: 10.1002/ccd.20303.
Drug-eluting stents.
Chieffo A, Colombo A.
Minerva Cardioangiol. 2002 Oct;50(5):419-29.
Embolic protection devices in saphenous vein graft interventions.
Cragun DT, Heuser RR.
J Interv Cardiol. 2006 Dec;19(6):525-9. doi: 10.1111/j.1540-8183.2006.00204.x.
Bivalirudin: pharmacology and clinical applications.
Shammas NW.
Cardiovasc Drug Rev. 2005 Winter;23(4):345-60. doi: 10.1111/j.1527-3466.2005.tb00177.x.
Guideliner catheter--friend or foe?
Murphy JC, Spence MS.
Catheter Cardiovasc Interv. 2012 Sep 1;80(3):447-50. doi: 10.1002/ccd.23261. Epub 2011 Dec 12.
Lost and found: Coronary stent retrieval and review of literature.
Malik SA, Brilakis ES, Pompili V, Chatzizisis YS.
Catheter Cardiovasc Interv. 2018 Jul;92(1):50-53. doi: 10.1002/ccd.27464. Epub 2018 Jan 4.
Restenosis after PCI. Part 1: pathophysiology and risk factors.
Jukema JW, Verschuren JJ, Ahmed TA, Quax PH.
Nat Rev Cardiol. 2011 Sep 13;9(1):53-62. doi: 10.1038/nrcardio.2011.132.
Gender differences in the outcome of cardiac interventions.
Tillmanns H, Waas W, Voss R, Grempels E, Hölschermann H, Haberbosch W, Waldecker B.
Herz. 2005 Aug;30(5):375-89. doi: 10.1007/s00059-005-2716-3.
Emerging drugs for acute myocardial infarction.
Lazzeri C, Tarquini R, Valente S, Abbate R, Gensini GF.
Expert Opin Emerg Drugs. 2010 Mar;15(1):87-105. doi: 10.1517/14728210903405619.
